Want to see ENTA full AI Analyst Report?
Total Valuation
Enanta Pharmaceuticals has a market cap or net worth of $399.54M. The enterprise value is $389.62.
Market Cap$399.54M
Enterprise Value$389.62
Share Statistics
Enanta Pharmaceuticals has 29,078,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,078,380
Owned by Insiders4.75%
Owned by Institutions0.12%
Financial Efficiency
Enanta Pharmaceuticals’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is -31.44%.
Return on Equity (ROE)-1.27
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-31.44%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee544.37K
Profits Per Employee-682.41K
Employee Count120
Asset Turnover0.23
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enanta Pharmaceuticals is ―. Enanta Pharmaceuticals’s PEG ratio is 0.10.
PE Ratio―
PS Ratio3.91
PB Ratio3.95
Price to Fair Value3.95
Price to FCF-7.94
Price to Operating Cash Flow-35.90
PEG Ratio0.10
Income Statement
In the last 12 months, Enanta Pharmaceuticals had revenue of 65.32M and earned -81.89M in profits. Earnings per share was -3.84.
Revenue65.32M
Gross Profit60.74M
Operating Income-85.35M
Pretax Income-83.55M
Net Income-81.89M
EBITDA-70.78M
Earnings Per Share (EPS)-3.84
Cash Flow
In the last 12 months, operating cash flow was -7.84M and capital expenditures -1.77M, giving a free cash flow of -9.61M billion.
Operating Cash Flow-7.84M
Free Cash Flow-9.61M
Free Cash Flow per Share-0.33
Dividends & Yields
Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.59
52-Week Price Change70.25%
50-Day Moving Average13.35
200-Day Moving Average13.23
Relative Strength Index (RSI)45.91
Average Volume (3m)132.86K
Important Dates
Enanta Pharmaceuticals upcoming earnings date is Aug 10, 2026, After Close (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Enanta Pharmaceuticals as a current ratio of 4.21, with Debt / Equity ratio of 160.07%
Current Ratio4.21
Quick Ratio4.21
Debt to Market Cap0.56
Net Debt to EBITDA-2.38
Interest Coverage Ratio-11.11
Taxes
In the past 12 months, Enanta Pharmaceuticals has paid -1.66M in taxes.
Income Tax-1.66M
Effective Tax Rate0.02
Enterprise Valuation
Enanta Pharmaceuticals EV to EBITDA ratio is -5.99, with an EV/FCF ratio of -13.19.
EV to Sales6.49
EV to EBITDA-5.99
EV to Free Cash Flow-13.19
EV to Operating Cash Flow-22.01
Balance Sheet
Enanta Pharmaceuticals has $163.77M in cash and marketable securities with $186.62M in debt, giving a net cash position of -$22.84M billion.
Cash & Marketable Securities$163.77M
Total Debt$186.62M
Net Cash-$22.84M
Net Cash Per Share-$0.79
Tangible Book Value Per Share$3.03
Margins
Gross margin is 98.25%, with operating margin of -130.65%, and net profit margin of -125.36%.
Gross Margin98.25%
Operating Margin-130.65%
Pretax Margin-127.90%
Net Profit Margin-125.36%
EBITDA Margin-108.35%
EBIT Margin-116.14%
Analyst Forecast
The average price target for Enanta Pharmaceuticals is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside42.76% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast7.37%
EPS Growth Forecast42.85%